PET/CT | Jotup

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Retrieved on:

Wednesday, April 10, 2024

Receptor (biochemistry), Cancer, Safety, Breast, MD, PET/CT, Patient, Neoplasm, MTIC, Therapy, Medical imaging

MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.

Key Points:

MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.
The Phase 1 dosimetry trial is evaluating the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancer.
“The Monopar team is quite excited about this trial initiation,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
We are very much looking forward to seeing the biodistribution and dosimetry data from this first-in-human study in advanced cancer patients.”
Further information about the MNPR-101-Zr trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

89th CMEF in Shanghai Elevates Global Medical Device Trade to The Next Level

Retrieved on:

Monday, April 15, 2024

Parkinson's disease, Exhibition, GE HealthCare, Machine learning, Robotics, James Parkinson, Collection, Deficit spending, Artificial intelligence, PET/CT, Disease, Central China, State Council, Multimedia, Diagnosis, IVD, Mobile robot

The exhibition served as a dynamic platform for collaboration, innovation, and exploration, significantly boosting global medical device trade.

Key Points:

The exhibition served as a dynamic platform for collaboration, innovation, and exploration, significantly boosting global medical device trade.
CMEF, over four decades, has grown into a multifaceted expo for the medical device industry, featuring innovation showcases, commercial trade, and knowledge exchange.
In 2023, China's medical device sector saw a 9.34% average growth rate in trade, with exports growing by 8.21% and imports increasing by 10.79%.
CMEF, as a global platform for trade cooperation, enables international exchanges, fostering cross-border trade, and supports multilateral collaborations in diverse sectors.

89th CMEF in Shanghai Elevates Global Medical Device Trade to The Next Level

Retrieved on:

Monday, April 15, 2024

The exhibition served as a dynamic platform for collaboration, innovation, and exploration, significantly boosting global medical device trade.

Key Points:

The exhibition served as a dynamic platform for collaboration, innovation, and exploration, significantly boosting global medical device trade.
CMEF, over four decades, has grown into a multifaceted expo for the medical device industry, featuring innovation showcases, commercial trade, and knowledge exchange.
CMEF, as a global platform for trade cooperation, enables international exchanges, fostering cross-border trade, and supports multilateral collaborations in diverse sectors.
It attracts participants from over 30 countries and regions, catalyzing technological and trade exchanges and supporting enterprises in accessing global markets.

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Retrieved on:

Friday, March 22, 2024

The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.

Key Points:

The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
As part of the trial, patients will take a daily fixed dose of 25 mg OATD-01 or placebo tablets for 12 weeks.
Patient safety will be monitored regularly through laboratory tests, neurological examinations and ECG and spirometry.
The study will involve approximately 20-30 centres in the US, the European Union, Norway and the UK.

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Retrieved on:

Tuesday, April 2, 2024

Software, Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, SMC, Safety, Lung cancer, Patient, BHCC, PET/CT, OTCQB, Cancer, MRI, NSCLC, GDT

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
Preliminary imaging results for this last patient in the first cohort, obtained six weeks after beginning treatment, show a favorable safety and tolerability profile, and promising early efficacy for the Deltacel™ treatment.
Additionally, the Deltacel-01 Safety Monitoring Committee (SMC) convened to analyze all preliminary patient data received to date and to determine the next phase of the trial.
This unanimous recommendation was based on encouraging preliminary data supporting Deltacel™ safety and tolerability, and evidence of anti-tumor activity.

GE HealthCare Announces the FDA Clearance of nCommand Lite by IONIC Health

Retrieved on:

Monday, March 25, 2024

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.

Key Points:

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.
IONIC Health’s nCommand Lite includes multi-modality capabilities in support of magnetic resonance (MR), computed tomography (CT), and positron emission tomography/CT (PET/CT) scanning.
To further enhance its remote operations portfolio, GE HealthCare launched an FDA-cleared new version of Digital Expert Access and announced an exclusive distribution agreement with IONIC Health in November 2023.
“We are thrilled that our nCommand Lite solution, built on the three-year-strong nCommand platform from Brazil, is now cleared for use in the U.S.,” said José Leovigildo Coelho, CEO and co-founder of IONIC Health.

GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

Retrieved on:

Thursday, March 14, 2024

The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.

Key Points:

The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.
The collaboration will increase patients’ access to GE HealthCare’s most current imaging technology, and may provide shorter scan times, reduced waiting times for care, and enable clinicians to have greater accuracy in diagnostic assessments.
The agreement also includes GE HealthCare patient monitoring, anesthesia, maternal infant care and diagnostic cardiology technologies.
GE HealthCare and Hartford HealthCare will also execute build-in-place upgrades with some existing MRI, CT, PET/CT, and X-rays to refresh older systems with fewer construction costs and while minimizing waste, equipment downtime, and disruption to patient care.

CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

Retrieved on:

Thursday, April 4, 2024

PET/CT, Trailer, Patient, PET, Hospital, Nature, CDL, Medicare, Physician, Medical imaging

WEXFORD, Pa., April 4, 2024 /PRNewswire/ -- CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.

Key Points:

WEXFORD, Pa., April 4, 2024 /PRNewswire/ -- CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer.
This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.
Positioned as a low-risk, high-value option, the Mobile Cardiac PET/CT Trailer is aimed at enhancing cardiac programs across various medical facilities and practices.
The Mobile Cardiac PET/CT Trailer marks CDL Nuclear Technologies' third flexible solution, which ranges from complete end-to-end PET/CT build-outs to mobile, on-demand daily use Rubidium-82 radioisotope services.

Hoag First in World to Enroll Prostate Cancer Patients in Molecular Imaging & Therapy Clinical Trials

Retrieved on:

Tuesday, April 2, 2024

Diagnosis, Molecular imaging, PET/CT, Prostate cancer, Patient, Prostate, Cancer, PSMA, Medical imaging

NEWPORT BEACH, Calif., April 2, 2024 /PRNewswire/ -- Hoag is the first site in the world to enroll patients in two clinical trials for prostate cancer staging and treatment.

Key Points:

NEWPORT BEACH, Calif., April 2, 2024 /PRNewswire/ -- Hoag is the first site in the world to enroll patients in two clinical trials for prostate cancer staging and treatment.
One trial focuses on molecular imaging and the other on molecular therapy; both are poised to redefine the standard of care for patients with prostate cancer worldwide.
"The MIRROR trial aims to bridge the gap in prostate cancer management by evaluating the utility of Pylarify imaging in favorable intermediate prostate cancer," said Gary A. Ulaner, M.D., Ph.D., F.S.N.M.M.I., F.A.C.N.M., the James & Pamela Muzzy Endowed Chair in Molecular Imaging & Therapy at the Hoag Family Cancer Institute.
This offers patients at Hoag unique access to leading-edge prostate cancer imaging and therapy options that aren't yet available in most cancer centers.

RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment

Retrieved on:

Thursday, February 29, 2024

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “Record Revenue and Adjusted EBITDA(1) in the fourth quarter enabled us to exceed our 2023 full-year revised guidance ranges, ranges that were increased several times throughout 2023.

Key Points:

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “Record Revenue and Adjusted EBITDA(1) in the fourth quarter enabled us to exceed our 2023 full-year revised guidance ranges, ranges that were increased several times throughout 2023.
Adjusted EBITDA(1) margins in the Imaging Center segment improved in the fourth quarter of 2023 relative to 2022 by 30 basis points, from 16.1% to 16.4%.”
“During 2023, we carefully managed liquidity and financial leverage.
Including our AI reporting segment, total company Revenue was $420.4 million in the fourth quarter of 2023, an increase of 9.5% from $383.9 million in last year’s fourth quarter.
For full-year 2023, RadNet reported Revenue from its Imaging Center reporting segment of $1,604 million and Adjusted EBITDA(1) Excluding Losses from the AI reporting segment of $245.1 million.